Oxaliplatin is widely used as a key drug in the treatment of colorectal cancer. However, its administration is associated with the dose-limiting adverse effect, peripheral neuropathy. Platinum accumulation in the dorsal root ganglion (DRG) is the major mechanism responsible for oxaliplatin-induced neuropathy. Some drug transporters have been identified as platinum complex transporters in kidney or tumor cells, but not yet in DRG. In the present study, we investigated oxaliplatin transporters and their contribution to peripheral neuropathy. We identified 12 platinum transporters expressed in DRG with real-time PCR, and their transiently overexpressing cells were established. After exposure to oxaliplatin, the accumulation of platinum in these overexpressing cells was evaluated using a coupled plasma mass spectrometer. Octn1/2-and Mate1-expressing cells showed the intracellular accumulation of oxaliplatin. In an animal study, peripheral neuropathy developed after the administration of oxaliplatin (4 mg/kg, intravenously, twice a week) to siRNA-injected rats (0.5 nmol, intrathecally, once a week) was demonstrated with the von Frey test. The knockdown of Octn1 in DRG ameliorated peripheral neuropathy, and decreased platinum accumulation in DRG, whereas the knockdown of Octn2 did not. Mate1 siRNA-injected rats developed more severe neuropathy than control rats. These results indicate that Octn1 and Mate1 are involved in platinum accumulation at DRG and oxaliplatininduced peripheral neuropathy.
Oxaliplatin, a platinum-based chemotherapeutic agent, is a key drug that is widely used to treat cancers of the digestive system. However, it causes severe acute and chronic peripheral neuropathies. In the early phase after its administration, acute neuropathy occurs in most patients and they develop cold hyperesthesia (Grothey 2005) . Acute neuropathy is induced by axonal abnormal excitability and alternations in the expression levels of voltage-gated Ca 2+ and K + channels, and not by neuronal injury (Wilson et al. 2002; Benoit et al. 2006; Kagiava et al. 2008; Leonard et al., 2005) . Recent studies reported that transient receptor potential-Ankyrin 1 (TRPA1) and -melastatin 8 (TRPM8) play important roles in oxaliplatin-induced acute cold hypersensitivity in rodents (Gauchan et al. 2009; Nassini et al. 2011; Zhao et al. 2012; Yamamoto et al. 2015) . Oxaliplatin induces reversible alteration of sodium channel activities in motor axons, and these changes are closely related to the cold hyperesthesia (Sittl et al. 2012; Deuis et al. 2013; Heide et al. 2018) . This acute neuropathy typically recovers within several days. After multiple cycles of oxaliplatin-based chemotherapy, patients develop chronic neuropathy, which is characterized by sensory neuropathy resulted in sensory ataxia and functional impairment (Pasetto et al. 2006) . This chronic neuropathy is a dose-limiting factor and often not only limits the activities of patients, but also results in the cessation of the long-term use of oxaliplatin-based chemotherapies (Saif and Reardon 2005) . Moreover, chronic neuropathy has been reported to persist for longer than 2 years in more than 10% of patients after the discontinuation of oxaliplatin treatments (Land et al. 2007 ). Thus, these neuropathies are serious clinical issues in oxaliplatin chemotherapy.
The anti-cancer effects of platinum drugs are due to their activities to form intra-or interstrand cross links with nuclear DNA. Platinum-DNA adducts inhibit transcription, cause apoptosis by arresting the cell cycle (Gill and Windebank 1998; Cavaletti et al. 2001; Argyriou et al. 2008) . A correlation has been reported between the accumulated levels of platinum drugs in dorsal root ganglion (DRG) and neurotoxicity (Ta et al. 2006) . DRG neurons requires a high level of active transcription in order to sustain its large size, high metabolic activity, and long axons. The inhibition of the transcription activity of DRG neurons is one of the main mechanisms responsible for oxaliplatin-induced peripheral neuropathy . Additionally, platinum has been shown to accumulate at higher levels in DRG neurons than in other nerve tissues (Jimenez-Andrade et al. 2008; McWhinney et al. 2009 ). Therefore, we focused on the mechanisms underlying oxaliplatin accumulation in DRG neurons that results in peripheral neuropathy.
Various drug transporters contribute to the influx or efflux of the platinum anti-cancer drugs, oxaliplatin, cisplatin, carboplatin, and their active forms. The copper transporters, Ctr1, Atp7a, and Atp7b, have been shown to modulate the accumulation of cisplatin, carboplatin, and oxaliplatin in cells (Komatsu et al. 2000; Samimi et al. 2004; Liu et al. 2009 ). The multidrug and toxin extrusion 1 (Mate1) transporter is encoded by the SLC47A1 gene and is expressed in the liver and the brush-border membrane of renal proximal tubules. The knockout of Mate1 was previously shown to increase platinum accumulation in the kidneys and induced more severe nephropathy in cisplatin-treated mice (Nakamura et al. 2010) . Organic cation transporters (Oct) and organic cation transporters novel type 1/2 (Octn1/2) mediate the intracellular uptake of many types of organic cations. In vitro studies have shown that Oct2 transports cisplatin and oxaliplatin (Zhang et al. 2006; Filipski et al. 2009; Burger et al. 2010; Sprowl et al. 2013) . In a recent study, the uptake of oxaliplatin and induction of cytotoxicity were reported to be regulated by Octn transporters (Jong et al. 2011) . Organic anion transporters (Oat) localize to the basolateral membranes of renal proximal tubules. Oats are necessary for the renal clearance of a broad range of exogenous substrates, and cisplatin-induced nephrotoxicity has been associated with the expression of Oats in the rat kidney (Ulu et al. 2012) . Drug transporters have been suggested to be associated with the accumulation of platinum; however, drug transportermediated oxaliplatin accumulation in DRG has not yet been investigated in detail.
In the present study, we examined the expression levels of drug transporters in DRG, and evaluated their contributions to oxaliplatin-induced peripheral neuropathy in rats.
Materials and methods

Animal care
Five-week-old male Sprague-Dawley rats weighing 180-250 g [Kyudo Co., Tosu, Japan; research resource identifier (RRID): RDG_13464272] were used in the present study. Animals were housed in groups of three or four per cage, with lights on from 07:00 to 19:00 h. The type of cage we used was white econ cage (CLEA Japan, Tokyo, Japan). Animals had free access to food and water in their home cages. All experiments were approved by the Experimental Animal Care and Use Committee of Kyushu University according to the National Institutes of Health guidelines (Permit Number: A28-255-0), and followed the International Association for the Study of Pain Committee for Research and Ethical Issues guidelines for animal research. All experimentation occurred during the light phase. Isoflurane was administered to reduce animal pain during surgeries and experiments (approximately 4% for induction and 2.5% for maintenance, oxygen 100%) in the same basic conditions. The criteria were employed to exclude rats with abnormal paw withdrawal threshold before oxaliplatin treatment, significant decrease in body weight by oxaliplatin treatment or difficulty in walking by the siRNA intrathecal injection. In our study, two animals were excluded. Our study was not pre-registered. 7, 8, 14, 15, 21, and 22) . Oxaliplatin was administered at a volume of 1 mL/kg of body weight. siRNA and atelocollagen complexes were injected intrathecally once a week for 5 weeks (day À7, 0, 7, 14, and 21) . Oxaliplatin and siRNA doses were selected based on previous studies (Sakurai et al. 2009; Takeuchi et al. 2013) .
Cell cultures
Quantitative real-time PCR mRNA levels were measured by real-time PCR using a StepOnePlus TM real-time PCR System (Applied Biosystems, Foster City, CA, USA). The sequences of the primers used in the present study are summarized (Table 1) . Amplification mixtures contained 5 lL of SYBR Premix Ex Taq (Takara, Kyoto, Japan, Cat. No. RR820A), 0.2 lL of Rox reference dye, 2 lL of a cDNA synthesis mixture, 2 pmol each of the forward and reverse primers, and distilled water in a total volume of 10 lL. Cycling conditions were as follows: 95°C for 30 s, followed by 40 cycles of amplification at 95°C for 5 s and at 60°C for 30 s. The specificity of the real-time PCR product was proven by a dissociation curve analysis. Triplicate measurements were performed for all samples. Realtime PCR data for each target gene quantity were calculated in the following manner. In absolute quantification, each 96-well assay plate contained unknown samples and sequentially diluted concentrations of the plasmid standard constructed, from which a standard curve was generated for the quantification of gene copy numbers in unknown samples. In order to compare gene expression levels among different samples, the amount of target mRNA was corrected relative to that of glyceraldehyde-3-phosphate dehydrogenase. Glyceraldehyde-3-phosphate dehydrogenase has been used as an internal reference in gene expression analyses using DRG (Matsuoka et al. 2007; Piller et al. 2013) .
Construction of transporter expression vectors
Transporter expression vectors were generated by inserting the PCR products of each transporter protein-coding region into the pcDNA3.1(+) vector and pcDNA5/FRT vector (Thermo Fisher Scientific K.K., . Amplified PCR products were digested and inserted into the multi-cloning site of each basic vector. Primer sets and restriction enzymes were described in Table 2 
of the Pt standard solution (Wako Pure Chemicals Ltd., Cat. No.
163-08121).
Western blotting Cells and DRG (n = 3) were homogenized with ristocetin-induced platelet agglutination buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, 0.5w/v% sodium deoxycholate, 0.1w/v% sodium dodecyl sulfate, 1.0w/v% NP-40, and 1 mM EDTA) and Protease Inhibitor Cocktail (Sigma-Aldrich). Lysate samples were separated on 9% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene membranes using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, Richmond, CA, USA).
Immunoblots were blocked in phosphate-buffered saline (PBS) with 0.1% Tween 20 and 5% non-fat dry milk at 27°C for 1 h and then incubated with the primary antibody against each transporter (polyclonal anti-MATE1, Santa Cruz Biotechnology, Inc., Dallas, TX, USA; poly-clonal anti OCTN1, Bioworld Technology, Inc., Louis Park, Minnesota, USA; poly-clonal anti OCTN2, Proteintech, Chicago, IL, USA, RRID: AB_2191406; b-actin monoclonal antibody, Cell Signaling Technology Japan, K.K., Tokyo, Japan, RRID: AB_10916696) at 4°C overnight. All primary antibodies were diluted 1 : 1000 with Can Get Signal Immunoreaction Enhancer Solution 1 (Toyobo, Osaka, Japan). Immunocomplexes were hybridized with an anti-rabbit or anti-mouse IgG horseradish peroxidase-linked whole antibody (GE Healthcare, Little Chalfont, Buckinghamshire, UK, Cat. No. NA934-1ML and NA931-1ML).
Membranes were washed three times in 0.5% Tween-PBS, and specific bands were visualized using the Amersham enhanced chemiluminescence Select Western Blotting Detection Reagent (GE Healthcare, Cat. No. RPN2109) according to the manufacturer's instructions. The band intensities were analyzed using a LAS-3000 imaging analyzer and Multi Gauge software version 3.2 (Fujifilm, Tokyo, Japan, RRID: SCR_014299).
Cell viability assay of Flp-In 293 cells overexpressing transporters
Flp-In 293 cells transfected with the transporters were seeded at a density of 4 9 10 3 cells/well on 96-well plates, and were used in experiments the next day. Flp-In 293 cells overexpressing the transporters were incubated in 10% fetal bovine serum-containing medium and exposed to oxaliplatin (0.1-1000 lM) for 72 h. Cells were washed with PBS after the treatment with oxaliplatin. In order to measure cell viability, 10 lL of CCK-8 assay solution (Dojindo Laboratory, Kumamoto, Japan, Cat. No. 347-07621) was added to 100 lL of medium per well and incubated for 1 h. The optical densities of the plates were then read on a microplate reader (Sunrise; TECAN Group Ltd., Mannedorf, Switzerland) using absorbance at 450 nm with a reference wavelength of 620 nm.
Assessment of PC12 neurite outgrowth PC12 cells were differentiated in the presence of nerve growth factor (100 ng/mL), and have previously been used as a model of oxaliplatin-induced neurodegeneration in vitro. PC12 cells were seeded at a density of 3 9 10 3 cells/cm 2 on 96-well plates (Falcon;
Becton Dickinson Co., Ltd., NJ, USA, Cat. No. 356461) and were used for testing on the third day. Cultured cells were exposed to oxaliplatin (0.1-1000 lM) for 24 h. They were stained with Alexa 
Fluor TM 488 Phalloidin (1 : 1000; Thermo Fisher Scientific K.K., RRID: AB_2315147) and Hoechst 33342 (1 : 1000; Dojindo, Cat. No. 346-07951) at 37°C for 1 h. Cells were monitored using ImageXpress (Molecular Devices Japan, Tokyo, Japan) and the lengths of neurites (number of neurites: between 600 and 1000) were measured using MetaXpress (Molecular Devices Japan).
Local injection of siRNA in rat DRG
The siRNAs of Octn1, Octn2, and Mate1 were obtained from Thermo Fisher Scientific K.K. In order to prevent the rapid degradation of siRNAs in the presence of nuclease in vivo and to support the carrier activities of siRNAs, AteloGene Local Use 'Quick Gelation' (KOKEN CO., LTD.) was used for the knockdown assay. Atelocollagen forms a complex with siRNA, and sustains local release for at least 1 week. Isoflurane was administered to reduce animal pain during experiments (approximately 4% for induction and 2.5% for maintenance, oxygen 100%), and the skin was disinfected using 70% ethanol to reduce skin microbes. siRNA (0.5 nmol) complexes with atelocollagen were intrathecally injected through a Hamilton syringe with a 27-g needle (Terumo Corporation, Tokyo, Japan) from 7 days prior to the administration of oxaliplatin. Three rats were used in each group (control-, Octn1-, Octn2-and Mate1-siRNA) for evaluating the knockdown efficiency of siRNA. siRNA sequences are described in Table 3. von Frey testing for mechanical allodynia We investigated the effects of transporter knockdown on mechanical allodynia using the von Frey test. Rats were allocated to three groups based on their basic withdrawal thresholds. Note that no randomization methods were employed in the allocation of animals to experimental groups, and the blinding of the experimenters did not take place in this study. An experimental timeline is seen in Fig. 1 . This test was performed before the first drug administration (day 0) and on days 7, 14, 21, and 28. Rats were placed in a clear plastic box (20 9 17 9 13 cm) with a wire mesh floor and allowed to habituate for 30 min prior to testing. Filaments (The Touch Test Sensory Evaluator Set; Linton Instrumentation, Norfolk, UK) with bending forces in the range of 1-15 g were applied to the midplantar skin of each hind paw six times, with each application being held for 6 s. The paw withdrawal threshold was assessed by a modified up-down method as previously reported (Kawashiri et al. 2011) . Six rats were used in each group.
Assessment of sciatic axonal degeneration
On days 28, sciatic nerves were harvested from rats. Surgery and experimental procedures on rats were performed under 2.5% isoflurane (v/v) anesthesia in the same basic conditions. Nerves were fixed in 2% (w/v) glutaraldehyde (Wako Pure Chemicals Ltd.) in 0.1 M phosphate buffer (pH 7.4, 4°C) for 4 h followed by washing with 0.1 M phosphate buffer. After 8% (w/v) sucrosesubstitution, each sample was cut into 5 mm length and embedded in paraffin. Paraffin blocks were sliced into 3 lm section, and each section was stained with 0.05% toluidine blue. Four sections were examined per mouse. Sample sections were evaluated using light microscopy (BX51; Olympus Corp., Tokyo, Japan). Axon area was calculated by image analysis software (Image J 1.36; Wayne Rasband, National Institutes of Health, Bethesda, MD, USA) from approximately 3000 to 6000 axons per group. Six rats were used in each group.
Statistical analysis
Samples without experimental errors were included, while samples having experimental errors and significant defect or disease caused by non-human factors were excluded. In box plots, the median is represented as the central bar of the box and the horizontal box edge lines mean the inter-quartile rage. No test for outliers was used; all data were included in the study. Preliminary assessment of normality of data (Shapiro-Wilk test) was performed when comparing two independent samples. In the animal study, data were analyzed using the Student's t-test, or two-way analysis of variance followed by the Tukey-Kramer test (StatView for Windows version 5.0; Abacus Concepts, Berkely, CA, USA) to assess the significance of differences among groups. The cell viability data of Flp-In 293 cells and neurite outgrowth measurements of PC12 cells are expressed as percentages of the vehicle-treated group. One-way ANOVA was used to compare the control with transporter-expressed cells and was followed by Dunnett's test for individual comparisons. Note that no sample size calculation was performed before the beginning of the study, and sample size was decided by reference to previous reports (Jong et al. 2011; Chen et al. 2014; Masuguchi et al. 2014) . p < 0.05 was accepted as being significant. 
Results
mRNA expression levels of drug transporters in rat DRG Twenty-one target transporters were reported to contribute to resistance to or the adverse effects of platinum agents (oxaliplatin, cisplatin, and carboplatin) through their transport mechanisms. We measured the mRNA expression of target transporters in DRG by quantitative real-time PCR (Table 4) . Twelve out of the 21 transporter genes examined were present at the levels quantitated (Ct value < 30).
Screening of oxaliplatin transport activity using transiently transfected cells
The expression vectors of 12 candidate transporters were transiently transfected into HEK-293 cells. We measured platinum accumulation levels in the transfected cells after their exposure to oxaliplatin. Octn1-, Octn2-, and Mate1-expressing cells showed significantly higher intracellular platinum accumulation levels than those of Mock (Fig. 2) .
Effects of transporter overexpression on the uptake of oxaliplatin and Pt(dach)Cl 2
We established Flp-In 293 cells stably expressing Octn1, Octn2, and Mate1. Protein expression was confirmed by western blotting (Fig. 3a) . Oxaliplatin concentration-dependent platinum accumulation was measured in stably expressing cells. The accumulation of platinum in expressing cells occurred in a manner that was dependent on the dose of oxaliplatin, with approximately three-to fivefold higher levels than those in mock-transfected cells (Fig. 3b) . Oxaliplatin is metabolized to dichloro(1,2-diaminocyclohexane) platinum (Pt(dach)Cl 2 ) and oxalate (Graham et al., 2000) . A previous study reported that Pt(dach)Cl 2 induced chronic neuropathy in rats (Sakurai et al. 2009 ). In the present study, we measured platinum accumulation levels in transporterexpressing cells after their exposure to Pt(dach)Cl 2 . The overexpression of transporters increased intracellular platinum accumulation levels over those in mock cells (Fig. 3c ).
Oxaliplatin-induced cytotoxicity and neurotoxicity in drug transporter-expressing cells
The CCK-8 assay was performed to evaluate the effects of transporters on oxaliplatin-induced cytotoxicity. Cell viability was significantly decreased in Octn1-, Octn2-, and Mate1-expressing Flp-In 293 cells after exposure to oxaliplatin (1 lM) for 72 h (Fig. 4a) . We established PC12 cells expressing Octn1, Octn2, and Mate1, and evaluated the effects of transporter expression on oxaliplatin-induced neurotoxicity by measuring the length of PC12 neurites. After an incubation with oxaliplatin (1, 3, and 10 lM) for 24 h, the lengths of neurite outgrowth was shorten in transporterexpressing PC12 cells than in mock-transfected cells (Fig. 4b) .
Contribution of drug transporters to oxaliplatin-induced peripheral neuropathy, platinum accumulation in rat DRG and sciatic nerve degeneration
We evaluated the contribution of drug transporter expression in rat DRG to oxaliplatin-induced peripheral neuropathy using a local injection of siRNA. Animals were intrathecally injected with the siRNA complex with atelocollagen, and L4-L6 DRG were collected on days 3 and 7 after the administration of siRNA. The results of western blotting showed that the intrathecal injection of Octn1, Octn2, and Mate1 siRNAs decreased protein expression to approximately 40-60% that with the vehicle treatment on day 7 in DRG ( Fig. 5 ). An i.v. injection of oxaliplatin was performed twice weekly for 4 weeks. The siRNA complex with atelocollagen was intrathecally injected from 7 days prior to the administration of oxaliplatin. The administration of oxaliplatin lowered the withdrawal threshold significantly more than the vehicle treatment on days 14, 21, and 28. The administration of Octn1 siRNA ameliorated oxaliplatin-induced reductions in the withdrawal threshold on days 14 and 21 (Fig. 6a) . The accumulation of platinum in DRG was decreased by the knockdown of Octn1 on day 28 (Fig. 6b) . The knockdown of Octn2 had no significant effects on oxaliplatin-induced peripheral neuropathy or platinum accumulation in DRG ( Fig. 6c and d) . The oxaliplatin injection induced peripheral neuropathy from day 14 in all groups. However, the knockdown of Mate1 resulted in significant reductions in the withdrawal threshold from that in the control group on day 21 (Fig. 6e) . The accumulation of platinum in DRG simultaneously increased in Mate1 knockdown rats (Fig. 6f) . Moreover, we measured the area of nerve fiber in rat sciatic nerve. The knockdown of Octn1 did not change average area of axons while increased the frequency of large size nerve fibers (Fig. 7a, Figure S2a and d) . On the other hand, the Octn2 knockdown did not change the size of nerve fibers compare with oxaliplatin treated group (Fig. 7b, Figure S2b and e). The administration of Mate1 altered average area of axons and distribution of the nerve fibers, and decreased the rate of large size fibers slightly (Fig. 7c, Figure S2c and f) . 1, 1, 10 , 100, and 1000 lM). Cell viability was measured using the CCK-8 assay (n = 5 or 6; number of cell culture dishes). *p < 0.05, **p < 0.01 significantly different from Mock. (b) PC12 cells were incubated with oxaliplatin (0.1, 0.3, 1, 3, and 10 lM) after a treatment with nerve growth factor (100 ng/mL) for 72 h (n = 6; number of cell culture dishes). *p < 0.05, **p < 0.01 significantly different from Mock. Each siRNA was intrathecally administered with AteloGene Local Use 'Quick Gelation'. Three or 7 days after the administration of siRNA, DRG were collected and the expression levels of transporters [OCTN1/2 and multidrug and toxic compound extrusion (MATE1)] were assessed by western blotting. A densitometric analysis was shown for transporter/b-actin of the blot (n = 3; number of rats). Fig. 6 Effects of transporter knockdown on oxaliplatin-induced peripheral neuropathy and platinum accumulation in dorsal root ganglion (DRG). Oxaliplatin (4 mg/kg, i.v.) was administered twice per week for 4 weeks (day 0, 1, 7, 8, 14, 15, 21, and 22) . Each siRNA was administered intrathecally once per week for 5 weeks (day À7, 0, 7, 14, and 21). (a, c and e) The von Frey test was performed before drug administration on days 0 and day 7, 14, 21, and 28. Values are expressed as the mean AE SEM (n = 6; number of rats). **p < 0.01 significantly different from Vehicle. † † p < 0.01 significantly different from Oxaliplatin. (b, d and f) DRG was harvested from oxaliplatin-treated rats on days 28 (b and d) and 21 (f). Platinum accumulation was measured by inductively coupled plasma mass spectrometer (n = 6; number of rats). *p < 0.05 significantly different from Oxaliplatin.
Discussion
In the present study, we examined oxaliplatin transporters in DRG using real-time PCR and measured platinum accumulation in HEK-293 cells transiently expressing transporters. Twenty-one candidate transporters were previously suggested to transport platinum agents. Based on the results of real-time PCR, we detected the expression of 12 transporters and identified their absolute expression levels ( Figure S1 ). The previous study indicated the involvement of Oct2 in oxaliplatin-induced acute neurotoxicity in mouse model (Sprowl et al. 2013) . On the other side, Koepsell et al. (2007) also reported that Oct2 mRNA expression was detectable in DRG tissue at levels approximately 200-fold lower than that in kidney, a known Oct2-expressing tissue. In our study, Oct1, Oct2, and Oct3 showed low mRNA expression levels in rat DRG tissue (Table 4 ), suggesting that Oct2 does not have an important role in oxaliplatin transport in DRG. Nishida et al. also measured mRNA levels in DRG and showed that there was no or only negligible expression of Oct1, 2, and 3 (2013). Methyl 4-phenylpyridinium is a transported substrate for OCT1-3, and tetraethylammonium bromide is a model substrate of OCT1-3 and OCTN1-2 (Koepsell et al. 2007) . The kinetics of uptake of methyl 4-phenylpyridinium into DRG was not significantly different in the culture temperature of 37 and 4°C, but the uptake of tetraethylammonium bromide in the temperature of 37°C was significantly higher than that in 4°C (Jong et al., 2011) . These results indicate that the contribution of Octn1 and 2 to the uptake of the substrate into DRG is greater than Octs. Only Octn1-, Octn2-, and Mate1-expressing HEK-293 cells showed higher intracellular platinum accumulation levels than those of mock-transfected cells. These results suggest that the drug transporters Octn1, Octn2, and Mate1 contribute to oxaliplatin transport and intracellular platinum accumulation. In HEK-293 cells expressing the transporters, Ctr1, Ctr2, Atp7a, Atp7b, Bcrp, Mdr1a, Mdr1b, and Mrp1, no significant differences were observed in intracellular platinum accumulation levels from mock-transfected cells. Previous studies reported that the copper transporters, Ctr1, Atp7a, and Atp7b, transport platinum agents (Song et al. 2004; Safaei and Howell 2005) ; however, the present results revealed the absence of significant oxaliplatin transport activity. Ip et al. suggested that the Ctr1 inhibitor, copper histidine, had no effect on platinum accumulation in DRG tissue. The relationship between copper transporters and oxaliplatin has remained controversial. The ATP-binding cassette sub family transporters, Bcrp, Mdr1a, Mdr1b, and Mrp1, are important transporters that cause chemotherapy resistance and adverse effects in treatments with platinum anticancer drugs (Ota et al. 2009; Ekblad et al. 2010; Wang et al. 2010) . However, the overexpression of ATP-binding cassette sub family transporters did not exert clear effects on the accumulation of oxaliplatin in the present study.
We established Flp-In 293 cells stably expressing Octn1, Octn2, or Mate1, and evaluated the effects of the transporters on intracellular platinum accumulation and cytotoxicity. FlpIn 293 cell is a HEK-293 cell clone with a Flp recombinant target integration cassette in the transcriptionally active locus. HEK-293 cells were widely used for the analysis of function of transporters, because they can be readily Fig. 7 Effects of transporter knockdown on oxaliplatin-induced degeneration of sciatic nerve fibers. Sciatic nerves were harvested from six rats treated with oxaliplatin and siRNA (a: Octn1, b: Octn2, c: Mate1) per each group on day 28, and stained with toluidine blue. The area of axon was measured using image analysis software (Image J 1.36) (n = 6; number of rats). *p < 0.05 significantly different from Vehicle.
transfected rather than primary cultured cells. Three transporters increased platinum accumulation levels from those in mock-transfected cells after exposure to oxaliplatin and Pt (dach)Cl 2 . This result suggests that Octn1, Octn2, and Mate1 transport oxaliplatin and its active metabolite. However, exposure to Pt(dach)Cl 2 resulted in lower platinum accumulation levels in overexpressing cells than to oxaliplatin exposure, suggesting that oxaliplatin contributes more to intracellular platinum accumulation than Pt(dach)Cl 2 . Previous studies indicated that the oxaliplatin decreases cell survival in DRG and degenerates neurite outgrowth in cultured PC12 cells and rat DRG (Ta et al. 2006; Kawashiri et al. 2011) . In cytotoxicity assays, exposure to 1 lM oxaliplatin resulted in more severe cell cytotoxicity in transporters-overexpressing cells than in mock-transfected cells. Furthermore, we evaluated the contribution of transporters to neurotoxicity by measuring the neurite outgrowth of PC12 cells. PC12 cells have been proved to be a useful cell model to study nervous physiology and pharmacology (Wang et al. 2015) . Because of the difficulty of establishment of primary cultured DRG cells expressing transporters, we used PC12 cells in this study. More severe neurotoxicity was observed in transporter-expressing PC12 cells following their exposure to 1, 3, and 10 lM oxaliplatin than in mocktransfected cells. These results suggest that the expression of Octn1, Octn2, and Mate1 in DRG affects oxaliplatin-induced peripheral neuropathy through the mechanisms of platinum accumulation, cell cytotoxicity, and neurotoxicity.
In our in vitro study, the expression of Octn1, Octn2, and Mate1 contributed to intracellular platinum accumulation, oxaliplatin-induced cytotoxicity, and neurotoxicity. In the animal study, we evaluated the functions of the transporters on oxaliplatin-induced neuropathy by knockdown in rat DRG. The protein expression of each transporter decreased by approximately 40-60% 7 days after the intrathecal administration of siRNA. The knockdown of Octn1 ameliorated oxaliplatin-induced peripheral neuropathy, and decreased platinum accumulation in rat DRG. This result indicates that Octn1 is an important transporter involved in oxaliplatin influx at DRG. A previous study suggested that Octn1 transports oxaliplatin into DRG cells (Jong et al. 2011) . The knockdown of Octn2 did not exert significant effects on oxaliplatin-induced reductions in the withdrawal threshold or platinum accumulation levels in DRG. Octn1 and Octn2 affected platinum accumulation, cytotoxicity, and neurotoxicity in transporter-expressing cells, whereas only the knockdown of Octn1 exerted effects on oxaliplatininduced neuropathy and platinum accumulation in rat DRG in the in vivo study. Octn1 is a multifunctional transporter that plays roles in pH-dependent cation transport and Na + -dependent ergothioneine transport (Tamai et al. 1997; Yabuuchi et al. 1999) . Proton and Na + conditions surrounding DRG cells remain unclear; however, spinal fluid has a slightly higher pH than that of standard intracellular conditions. Octn1-mediated oxaliplatin influx in the present study was considered based on the pH-dependent transport mechanism. A previous study reported that Octn2-mediated cation transport functioned together with Na + /carnitine cotransport (Ohashi et al. 1999 (Ohashi et al. , 2001 . Carnitine uptake and concentrations were shown to be significantly lower in nerve tissue than in other tissues, such as the kidney, liver, heart, and lungs (Yokogawa et al. 1999) . These findings suggest that Octn2 transport activity based on Na + /carnitine cotransport in nerve tissues is weak. Jong et al. (2011) reported that Octn1-mediated oxaliplatin transport contributed more to platinum accumulation and neurotoxicity than Octn2 in primary cultured DRG cells. Our results also showed that Octn2 had a limited influence on oxaliplatin transport and neuropathy in rat DRG. Collectively, these results suggest that Octn1 is one of the major oxaliplatin influx transporters in DRG and contributes to oxaliplatin-induced neuropathy.
A Mate1 siRNA injection into rat DRG caused more severe oxaliplatin-induced neuropathy and platinum accumulation than the control-siRNA treatment. These results suggest that Mate1 plays an important role in the efflux of oxaliplatin. Mate1 is a major transporter contributing to the renal and biliary excretion of endogenous and exogenous organic cations, including a number of therapeutic drugs (Tanihara et al. 2007) . A previous study revealed that Mate1 was involved in cisplatin transport and its nephropathy (Nakamura et al. 2010 ). Our results indicate that similar to cisplatin, Mate1 exhibits oxaliplatin efflux and detoxification activities. Platinum levels in the cells and DRG treated with platinum agents correlate with the severity of cytotoxicity and neurotoxicity (Gregg et al. 1992; Dzagnidze et al. 2007) . In our in vitro study, cell viability was significantly decreased in Mate1-expressing Flp-In 293 cells after exposure to oxaliplatin (Fig. 4a) , though Mate1 knockdown exacerbated mechanical allodynia in vivo (Fig. 6e) . This discrepancy could be explained by the intracellular platinum accumulation. The overexpression of Mate1 increased intracellular platinum accumulation levels after exposure to oxaliplatin in the in vitro study (Fig. 3) , whereas Mate1 played a role in the efflux of oxaliplatin in rat DRG in the in vivo study (Fig. 6f) . Mate1 is generally regarded as a H + / cation exchange transporter and transports its substrates in a proton gradient-dependent manner (Tsuda et al. 2007) . However, Mate1 is expressed in bone marrow, skeletal muscle, glia, and Langerhans alpha cells, which have no gradient of protons across the plasma membrane (Otsuka et al. 2005; Hiasa et al. 2006) . A recent study revealed that proton and substrate exchange transport by Mate1 depends on substrate concentrations (Terada et al. 2006 ). Exposure to a high concentration of oxaliplatin in the in vitro assay may have been responsible for the elevated intracellular platinum accumulation levels in Mate1-overexpressing cells. Oxaliplatin has a short elimination half-life in plasma (Ehrsson et al. 2002) and accumulates in DRG at high concentrations after repeated oxaliplatin injections in vivo (Screnci et al. 2000) . Our animal study showed that the prolonged administration of oxaliplatin resulted in high platinum concentrations in DRG, suggesting that DRG has an intracellular to extracellular concentration gradient. These results indicate that oxaliplatin is exported from DRG to outside the cell by Mate1 in a manner that depends on the concentration gradient. Further studies are needed in order to elucidate the relationship between the localization of Mate1 in DRG and transport direction of oxaliplatin.
Chemotherapy-induced neuropathies were evaluated in various ways, von Frey test for mechanical allodynia, rotarod test for motor functions, hot plate test for thermal allodynia, electrophysiological measurements, or morphometric assessment of DRG cells or sciatic nerve (Marmiroli et al. 2012; Balayssac et al. 2014; Choi et al. 2017) . The neurotoxicity induced by platinum anticancer drugs is characterized by a dose-dependent painful sensory neuropathy (Gamelin et al. 2002) . In our study, the degeneration of sciatic nerves and mechanical allodynia were occurred by oxaliplatin administration (Fig. 7) . Same as these symptoms of oxaliplatin-induced neuropathy, Octn1 and Mate1 might have effects on oxaliplatin dosedependent neuropathic symptoms.
Previous reports revealed that oxaliplatin treatment caused significant changes in size profiles of large-sized neurons in DRG tissue, and decreased frequency of larger cells and an increased frequency of smaller cells (Ip et al. 2013) . Moreover, DRG cell body size and axonal area are positively correlated (Jamieson et al. 2005) . Based on our results, large size sciatic nerve fibers were increased in Octn1 knockdown rats and slightly decreased in Mate1 knockdown rats (Fig. 7a-c ). Octn1 and Mate1 might express in large-size DRG cells; however, the localization of them in DRG tissue have not been clarified. Recent study reported that OCTN1 and 2 were expressed by all types of DRG neurons (Nishida et al. 2018) . So further studies are needed in order to elucidate the relationship between the localization of transporters and oxaliplatin-induced neuropathy.
In conclusion, Octn1, Octn2, and Mate1 exhibited oxaliplatin transport activities, and Octn1 and Mate1 may be responsible for oxaliplatin-induced peripheral neuropathy in rats. Octn1 contributes to oxaliplatin influx, while Mate1 functions as an oxaliplatin efflux transporter. An Octn1 inhibitor and inducer of Mate1 expression may contribute to the prevention of oxaliplatin-induced peripheral neuropathy. The ion channel inhibitors, verapamil, and quinidine, are major Octn1 inhibitors. A previous study reported that the kinin B1 receptor inhibitor, R715 increased the expression of Mate1 in the kidneys and mitigated cisplatin-induced nephropathy (Estrela et al. 2017) . Thus, these compounds may be effective at preventing the accumulation of oxaliplatin in neuronal cells and ameliorating peripheral neuropathy. Further studies with a focus on drug transporters are needed in order to establish a new therapeutic target for oxaliplatin-induced neuropathy.
